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reported in somatic NRAS- and KRAS-
driven neoplasms (Reifenberger et al.,
2004; Palomba et al., 2012).
Our identiﬁcation of somatic RAS
mutations in vascular tumors has clinical
relevance. Current therapies against
these lesions are limited to steroids and
β-blockers, which achieve mixed results,
often limited to tumor size reduction
without resolution (Wine Lee et al.,
2014). Some infantile vascular tumors,
such as VASC101, are unresponsive to
such interventions (Wine Lee et al., 2014).
These cases may harbor RAS mutations,
and might respond to farnesyl transferase
inhibitors or Raf/Mek/Erk inhibitors, which
block signaling upstream or downstream
of RAS. The ﬁnding that RAS mutation
drives vascular tumors provides potential
opportunities to develop targeted therapies
for current drug-resistant lesions.
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TO THE EDITOR
Chronic diabetic ulcers remain an
intractable clinical problem that leads
to signiﬁcant morbidity and mortality
throughout the world. Selection of an
appropriate treatment strategy that is
individually tailored to each patient
from the hundreds of choices available
in the market is critical to success in
wound care. However, there is cur-
rently no objective measurement that
can reliably predict healing outcome in
chronic diabetic ulcers, making such aAccepted article preview online 3 February 2015; published online 26 February 2015
Abbreviations: ANOVA, analysis of variance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
MMP, matrix metalloprotease
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“personalized medicine” approach vir-
tually impossible.
Researchers working to identify diag-
nostic biomarkers have found several
factors that are associated with clinical
outcome, including elevated levels of β-
catenin, matrix metalloproteases (MMPs),
and microbiome complexity in nonheal-
ing wounds (Eming et al., 2014).
However, the search for a biomarker
signature that can accurately and robustly
predict healing outcome remains elusive.
Taking cues from recent literature identi-
fying abnormal macrophage behavior in
diabetic ulcers (see, e.g., Miao et al.,
2012; Mirza et al., 2014), we set out to
determine whether this ﬁnding could be
applied to identify a healing signature.
Macrophages are the central cells of
the inﬂammatory response and are
recognized as primary regulators of
wound healing (Koh and DiPietro,
2011). Macrophages exist in a spec-
trum of functional phenotypes ranging
from proinﬂammatory, or “M1”, to anti-
inﬂammatory and prohealing, or “M2”,
each orchestrating events speciﬁc to the
stage of repair (Mosser and Edwards,
2008). Several studies have shown that
wound macrophages undergo a pheno-
typic shift from M1 to M2 during the
normal process of cutaneous wound
healing, and that this transition is
defective in diabetic ulcers (Mirza
et al., 2013; Wood et al., 2014). Thus,
we hypothesized that temporal changes
in the relative expression of proinﬂam-
matory and antiinﬂammatory genes
might be useful in distinguishing bet-
ween healing and nonhealing chronic
diabetic ulcers.
Diabetic patients, recruited from
Drexel University Wound Healing Cen-
ter, provided written consent in com-
pliance with the study protocol
approved by Drexel University Institu-
tional Review Board (please see
Supplementary Materials and Methods
for study design and methods). In a pilot
study of 10 patients with chronic
diabetic foot ulcers, we measured the
longitudinal expression of four proin-
ﬂammatory genes (VEGF, CCR7, CD80,
and IL1B) and three antiinﬂammatory
genes (MRC1, PDGFB, and TIMP3) that
were previously identiﬁed to be differ-
entially expressed between M1 and M2
macrophages in vitro (Spiller et al.,
2014; Spiller et al., 2015). These genes
were tracked over 4 weeks of standard
treatment between ulcers that ultimately
healed and those that did not heal
within 12 weeks of treatment. Proﬁle
analysis revealed no signiﬁcant differ-
ences in temporal expression of indivi-
dual genes in healing versus nonhealing
ulcers (Figure 1). These inconclusive
results highlight the difﬁculties in track-
ing gene expression in inherently het-
erogeneous tissues that are subject to
sampling variability.
To quantify the relative expression of
these genes, we devised an algorithm that
would simultaneously normalize the data
while combining information of the entire
panel of genes into a single score. We
used macrophages that were cultivated
and polarized to M1 and M2 phenotypes
in vitro as “positive controls” to avoid the
possibility of overﬁtting to the clinical data
(Figure 2a). We deﬁned the score as the
ratio of the sum of the raw values of M1
gene expression relative to the house-
keeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) to the sum of
the raw values of M2 gene expression
relative to GAPDH (M1/M2), such that
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Figure 1. Expression proﬁling of individual genes does not differentiate between healing and nonhealing chronic diabetic ulcers. Temporal gene expression
relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in healing versus nonhealing chronic diabetic ulcers (mean± SEM, n= 5 per group; note that
the y axis is log scale).
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its value was higher for M1 macro-
phages and lower for M2 macrophages
(Po0.0001, t-test, n=5) (Figure 2b). Not
surprisingly, we found that genes that were
not differentially regulated between M1
and M2 macrophages did not affect
the score (data not shown). When we
used this M1/M2 score to transform
gene expression data from a longitudinal
study of human burn wounds using
publicly available data (Greco et al.,
2010), we found that the score increased
immediately after injury and then
decreased after 4–7 days (Po0.05, one-
way analysis of variance (ANOVA) with
Tukey’s post hoc analysis, n=3;
Figure 2c). These results are in agree-
ment with studies describing the sequen-
tial proﬁle of M1 and M2 macrophages
in animal and human models of
acute wound healing (Deonarine et al.,
2007; Troidl et al., 2009; Novak and Koh,
2013).
Surprisingly, we found that the
initial value of the score was signiﬁ-
cantly higher for wounds that ultima-
tely healed compared with those that
did not (Po0.01, two-way ANOVA with
Sidak post hoc analysis, n=5; Figure 2d).
These results suggest that inﬂammation is
beneﬁcial for healing, and this is sup-
ported by the clinical practice of wound
debridement to stimulate inﬂamma-
tion and the contraindication of anti-
inﬂammatory treatments (Stadelmann
et al., 1998). Moreover, a delay in the
administration of antiinﬂammatory treat-
ments after an initial proinﬂammatory
period has been shown to be beneﬁcial
for healing in diabetic animal models
(Mirza et al., 2013; Jetten et al., 2014).
From a translational perspective, these
results also suggest that this score might
have the potential to identify those
wounds that are more likely to respond
to conservative treatment versus those
that may beneﬁt from a more aggressive
approach.
Subsequently, the M1/M2 scores in
healing and nonhealing ulcers followed
very different trends, with the score
decreasing for healing ulcers and
increasing for nonhealing ulcers
(Figure 2e). The mean fold changes in
the scores were signiﬁcantly different
between healing and nonhealing ulcers
as early as 2 weeks from the initial time
point (Po0.01, two-way ANOVA with
Sidak post hoc analysis, n= 5). In fact,
the mean fold change in the M1/M2
score at 4 weeks was 90 times higher
for nonhealing ulcers compared with
healing ulcers (Po0.0001, two-way
ANOVA with Sidak post hoc analysis,
n= 5; Figure 2f). The change in the
score at 4 weeks accurately predicted
healing or nonhealing by 12 weeks in
all 10 patients in this pilot study (100%
positive and negative predictive value,
using a fold change of o1 to indicate
healing and a fold change of 41 to
indicate nonhealing). By comparison,
Wound Healing Society guidelines
recommend using a 40% reduction in
wound area after 4 weeks of treatment
as an indicator of healing, a diagnostic
method that has been shown to have
only 50–70% positive predictive value
and 80–90% negative predictive value
(Sheehan et al., 2003; Cardinal et al.,
2008).
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Figure 2. A combinatorial M1/M2 score reveals major differences between healing and nonhealing chronic diabetic ulcers. (a) Gene expression of
macrophages polarized in vitro to the M1 or M2 phenotypes (mean± SEM, n= 5). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (b) Conversion of data in
(a) to a combinatorial M1/M2 score. (c) Change in M1/M2 score (relative to normal skin) over time in acute wounds (mean± SEM, n=3 pooled data from 15
samples), using data from Greco et al. (2010). Black asterisks indicate signiﬁcance compared with normal skin. (d) M1/M2 score in healing and nonhealing
diabetic ulcers over time. (e) Fold change in the M1/M2 score relative to the ﬁrst time point. (f) Mean fold change of M1/M2 score at 4 weeks. Data in (d–f) are
represented as mean± SEM, n= 5 per group. Black asterisks indicate signiﬁcance between healing and nonhealing groups, whereas blue and red asterisks
indicate differences over time within groups. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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Although preliminary, these results
suggest that quantitative analysis of
inﬂammatory gene expression may
have potential for use as a diagnostic
to complement the physician’s assess-
ment and discretion in the clinic. Future
studies with a larger cohort of patients
are required to optimize the algorithm
and to understand the contribution of
each gene to sensitivity and speciﬁcity.
CONFLICT OF INTEREST
The authors state no conﬂict of interest.
ACKNOWLEDGMENTS
We thank Dr Mahdi Sarmady, Dr Pichai Raman,
Ramakrishnan Rajagopalan, and Krista Spiller for
helpful discussions, and Jason Sedlak, Elena Nasto,
Nathan Tessema Ersumo, Sumati Nadkami, Jane
McDaniel, Lori Jenkins, and Lisa Flowers-Morrison
for help with patient enrollment and sample collec-
tion. We gratefully acknowledge support from the
Drexel-Coulter Translational Research Partnership.
Sina Nassiri1, Issa Zakeri2,
Michael S. Weingarten3 and
Kara L. Spiller1
1School of Biomedical Engineering Science and
Health Systems, Drexel University,
Philadelphia, Pennsylvania, USA; 2Department
of Epidemiology and Biostatistics, Drexel
University, Philadelphia, Pennsylvania, USA
and 3Department of Surgery, Drexel University
College of Medicine, Philadelphia,
Pennsylvania, USA
E-mail: spiller@drexel.edu
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Cardinal M, Eisenbud DE, Phillips T et al. (2008)
Early healing rates and wound area measure-
ments are reliable predictors of later complete
wound closure. Wound Repair Regen 16:
19–22
Deonarine K, Panelli MC, Stashower ME et al.
(2007) Gene expression proﬁling of cutaneous
wound healing. J Transl Med 5:11
Eming SA, Martin P, Tomic-Canic M (2014) Wound
repair and regeneration: mechanisms, signal-
ing, and translation. Sci Transl Med 6:265sr6
Greco JA 3rd, Pollins AC, Boone BE et al. (2010) A
microarray analysis of temporal gene expres-
sion proﬁles in thermally injured human skin.
Burns 36:192–204
Jetten N, Roumans N, Gijbels MJ et al. (2014)
Wound administration of M2-polarized macro-
phages does not improve murine cutaneous
healing responses. PLoS One 9:e102994
Koh TJ, DiPietro LA (2011) Inﬂammation and
wound healing: the role of the macrophage.
Expert Rev Mol Med 13:e23
Miao M, Niu Y, Xie T et al. (2012) Diabetes-
impaired wound healing and altered macro-
phage activation: a possible pathophysiologic
correlation. Wound Repair Regen 20:203–13
Mirza RE, Fang MM, Ennis WJ et al. (2013) Blocking
interleukin-1beta induces a healing-associated
wound macrophage phenotype and improves
healing in type 2 diabetes. Diabetes 62:
2579–87
Mirza RE, Fang MM, Weinheimer-Haus EM et al.
(2014) Sustained inﬂammasome activity in
macrophages impairs wound healing in type
2 diabetic humans and mice. Diabetes 63:
1103–14
Mosser DM, Edwards JP (2008) Exploring the full
spectrum of macrophage activation. Nat Rev
Immunol 8:958–69
Novak ML, Koh TJ (2013) Macrophage phenotypes
during tissue repair. J Leukoc Biol 93:875–81
Sheehan P, Jones P, Caselli A et al. (2003) Percent
change in wound area of diabetic foot
ulcers over a 4-week period is a robust
predictor of complete healing in a 12-week
prospective trial. Diabetes Care 26:1879–82
Spiller KL, Anfang RR, Spiller KJ et al. (2014) The
role of macrophage phenotype in vasculariza-
tion of tissue engineering scaffolds. Biomater-
ials 35:4477–88
Spiller KL, Nassiri S, Witherel CE et al. (2015)
Sequential delivery of immunomodulatory
cytokines to facilitate the M1-to-M2 transition
of macrophages and enhance vascularization
of bone scaffolds. Biomaterials 37:194–207
Stadelmann WK, Digenis AG, Tobin GR (1998)
Physiology and healing dynamics of chronic
cutaneous wounds. Am J Surg 176:26S–38S
Troidl C, Mollmann H, Nef H et al. (2009)
Classically and alternatively activated macro-
phages contribute to tissue remodelling after
myocardial infarction. J Cell Mol Med 13:
3485–96
Wood S, Jayaraman V, Huelsmann EJ et al. (2014)
Pro-inﬂammatory chemokine CCL2 (MCP-1)
promotes healing in diabetic wounds by
restoring the macrophage response. PLoS
One 9:e91574
www.jidonline.org 1703
YH Lim et al.
Gene Expression Signature in Human Diabetic Ulcers
